TD Cowen lowered the firm’s price target on Exagen (XGN) to $10 from $13 and keeps a Buy rating on the shares. The firm updated its model to to reflect the4Q preannouncement where volumes were strong but price missed as the drag of a large direct bill client converting to commercial billing is pressuring pricing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen price target lowered to $10 from $15 at BTIG
- Exagen price target lowered to $8 from $18 at B. Riley
- 3 ‘Strong Buy’ Stocks to Buy Now, 1/26/2026, According to Top Analysts
- Exagen: Temporary Headwinds, Strong AVISE Volume, and Undervalued Long‑Term Upside Support Buy Rating and $15 Target
- Exagen Announces Record 2025 Revenue and Strong Cash Position